Medicine

Bortezomib for Multiple Myeloma Can Cause Reactivation of Viruses

Georg Härter
Georg Härter

REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
GEORG HÄRTER, University Hospital, Ulm
For patients with multiple myeloma being treated with the proteasome inhibitor bortezomib, doctor’s should be wary of viral reactivation – and they should give antiviral prophylaxis in all cases. This finding was unveiled at ICAAC by Georg Härter from the University Hospital in Ulm, and he shared his data with Derek Thorne.

Similar Interviews

  • “Total Therapy” Possible Cure For Multiple Myeloma?
  • Bart Barlogie Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 BART

  • Targeted Therapies in Multiple Myeloma Treatment Decisions
  • Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma

  • Multiple Myeloma: Towards A Chronic Disease With Cure On The Horizon
  • Kenneth Anderson Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 KENNETH

    Post a comment

    Subscribe to Audio Medica Podcast